French regulator, ANSM, as well as Ethics Committee, CPP, have cleared ABX464 for Phase 2b/3 “miR-AGE” testing

The anti-inflammatory mechanism of action could prevent and treat cytokine storm and hyper-inflammation, which lead to acute respiratory distress syndrome (ARDS) and death of COVID-19 patients

New data show ABX464 inhibits SARS-CoV-2 viral replication in vitro in a human respiratory epithelium model, making ABX464 a molecule with a potential triple action, antiviral, anti-inflammatory and tissue repair

50 French and European clinical trial sites to treat high-risk patients with complications early

Rigorous, randomized and placebo-controlled miR-AGE trial will include 1,034 patients with convenient oral administration

Discussions being finalized with Bpifrance and SGPI for ABX464 COVID-19 project grant funding